HER-2 Binding Antibodies

Monoclonal antibody that specifically binds to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer HER2 binding specificity, comprising:

• a) a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and CDR-H3 wherein the CDR-H1 region comprises an amino acid sequence according to the formula:
• (S/N)1-(Y/S)2-(N/A/G/Y)3-(M/V/Y)4-(G/A/S/M)5-(0/-C)6
• wherein the CDR-H2 region comprises an amino acid sequence according to the formula:
• (I/C)1-(I)2-(N/S/Y)3-(H/A/S/G)4-(G/I/S)5-(D/G/S)6-(N/T/F/D/S)7-(T/A/N/S)8-(Y/H/T/S)9-(T/Y/W)10-(F/A/Y)11-(S/A/Y)12-(W/A/S)13-(W/A/S)14-(K/A/W)15-(G/A/K)16-(0/G/K)17 -(0/AG)18
• and wherein the CDR-H3 region comprises an amino acid sequence according to the formula:
• (G/S/A/D)1-(A/Y/D/V/L/Q)2-(A/T/D/V/Y/I)3-(P/A/S/G/Y)4-(G/N/S/D)5-(D/G/S/Y)6-(G/T/N/L/S)7-(R/A/G)8-(Y/F/L/G)9-(0/N/G/Y)10-(0/I/Y/L)11-(0/F)12-(0/S)13-(0/L)14
• b) a light chain variable region (VL) comprising CDR-L1, CDR-L2, and CDR-L3,
• wherein the CDR-L1 region comprises an amino acid sequence according to the formula:
• (Q)1-(A)2-(S)3-(Q)4-(S)5-(I)6-(G/S/Y)7-(T/N/S/I)8-(Y/A/L)9-(L)10-(G/A/S)11
• wherein the CDR-L2 region comprises an amino acid sequence according to the formula:
• (G/Y/S/K)1-(A)2-(S)3-(N/S/T)4-(L)5-(E/A)6-(F/S)7
• and wherein the CDR-L3 region comprises an amino acid sequence according to the formula:
• (Q)1-(C/N/S)2-(S/T/N)3-(A/D/N/Y)4-(Y/V/A/G)5-(G/S)6-(G/S)7-(R/N/V/Y/S)8-(Y/S)9-(V/S/L)10-(G/A/W)11-(G/A/T/F/E)12-(0/G)13-(0/A)14